Sight Diagnostics
PrivateLast Round
Series D
Aug 5, 2020
Total Funding Raised
$120.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sight Diagnostics operates in Healthcare & Life Sciences and is based in Tel Aviv. Its latest recorded funding round was a Series D round in August 2020.
Sight Diagnostics is a health tech company that develops automated microscopy devices and AI-powered platforms for rapid, lab-grade blood testing.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Computer Vision, Medical AI
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sight Diagnostics Comparables
Compare Sight Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Truvian | 83% | |
| Ozelle Diagnostics | 81% | |
| Ad Astra Diagnostics | 81% |
For institutional investors. Book with your work email.
Sight Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 5, 2020 | ||||
| Series C | Feb 14, 2019 | ||||
| Series B | Aug 1, 2016 | ||||
| Series A | Apr 8, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sight Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Alliance Capital | Series C, Series B |
| Clal Biotechnology Industries | Series C, Series A, Series D |
| Innovation Endeavors | Series A |
| GO Capital | Series C |
| Clal Industries | Series D |
| Clal Insurance Enterprises Holdings Ltd. | Series D |
| Longliv Ventures | Series C, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 190% MoM, reaching 3.1K.
- Jun 19, 2026
Monthly visitors grew 382% MoM, reaching 2.6K.
For institutional investors. Book with your work email.
Sight Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sight Diagnostics's valuation, stock price, and market status.
Is Sight Diagnostics a public or private company?
Sight Diagnostics is a private company.
What is the current stock price of Sight Diagnostics?
Sight Diagnostics is a private company, so its shares have no public market price. Caplight tracks Sight Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sight Diagnostics worth (valuation)?
Valuation information for Sight Diagnostics is not publicly available.
Can I buy Sight Diagnostics stock?
Sight Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sight Diagnostics's last funding round?
Sight Diagnostics's most recent funding round was Series D on August 5, 2020.
Who are the main investors in Sight Diagnostics?
Key investors in Sight Diagnostics include Longliv Ventures, Koch Disruptive Technologies.
Will Sight Diagnostics IPO soon?
No public IPO plans have been announced for Sight Diagnostics.
How can I track Sight Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in Sight Diagnostics's shares on secondary markets.